March 3, 2026Open Access

Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management

Puntos clave

Lithium levels may increase during the switch from semaglutide to tirzepatide, posing risks of toxicity.
Monitoring is essential, especially when initiating or changing doses of GLP-1-modulating agents.
Pharmacokinetic studies are necessary to understand the mechanisms of interaction between lithium and GLP-1 agents.
Increased vigilance is recommended to prevent adverse effects during changes in weight management treatment.

Resumen

Clinicians should be vigilant when initiating or switching GLP-1-modulating agents in patients receiving lithium. Pharmacokinetic studies are needed to clarify the mechanism of this interaction. Until more is known, increased monitoring of lithium levels is warranted, with initiation of a GLP-1-modulating agent, a dose change, or switching to another agent.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Jesse Burson

Jonathan G. Leung

Journals

Mental Health Clinician

Actions

Institutions

Mayo Clinic

Mayo Clinic in Arizona

Mayo Clinic in Florida

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management

Puntos clave

Resumen

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study